however , data are insufficient regarding the relative efficacy of regional vs systemic administration , the proper dose of activator administered regionally , the therapeutic role of the plasma lytic state during regional therapy , the incidence of serious bleeding , and the potential for simpler therapy using new activators with fibrin specificity .
C0032105
plasma
C0015982
fibrin